M.D. Sass Exits Sallie Mae -- Selling Its Entire $33.1 Million Stake

M.D. Sass fully exited SLM in Q1 2026, selling 1,399,804 shares for an estimated $33.1 million and cutting its stake from 3.0% of AUM to 0%. The move comes despite SLM reporting solid Q1 2026 results, with diluted EPS up to $1.54 from $1.40 a year earlier and private education loan originations rising 5%, while management raised full-year EPS guidance to $3.10-$3.20. The stock is still down about 29% over the past year, underperforming the S&P 500 by roughly 52 percentage points.

Analysis

The more important signal here is not the sale itself, but the kind of holder doing the selling: a diversified institutional portfolio exiting a mid-cap lender after a prolonged drawdown usually reflects a tightening of risk budgets, not necessarily a fundamental “fraud” call. That matters because SLM is still a levered proxy on credit normalization and student-loan demand, so incremental selling pressure can persist even after the headline filing if performance-chasing managers continue to de-risk into weakness. In other words, the flow overhang can outlast the fundamental thesis by several quarters.

The second-order risk is that SLM’s earnings quality is more cyclical than the headline EPS suggests. A flat-to-improving quarter can coexist with a deteriorating medium-term setup if originations growth slows, funding costs stay sticky, and the market keeps assigning a lower multiple to a policy-sensitive lender with limited growth duration. The stock’s underperformance has likely already compressed expectations, but that also means the next leg is driven less by absolute results and more by guidance durability and any sign that credit costs or deposit competition are stabilizing.

Consensus may be underestimating how much of the upside is already in the numbers after the recent bounce in operating metrics, while still overstating the probability of a clean multiple re-rate. If student lending policy remains noisy, SLM can look optically cheap for a long time without becoming cheap enough to attract incremental capital. The better setup is either a decisive catalyst on guidance/credit or a capitulation flush that resets positioning more fully; absent that, this remains a stock where “good enough” fundamentals can still fail to outperform.

From a relative-value perspective, the better expression is not an outright hero long, but a spread trade versus a higher-quality financial compounder or a sector basket. If flows keep favoring diversified cash generators while cyclicals lag, SLM likely remains capped until the market sees another quarter of stable credit and originations momentum. That creates a tradable window, but not necessarily an investable long-term re-rating yet.

Key Decisions for Investors

• Avoid initiating a standalone long in SLM here; wait 1-2 quarters for either credit-cost stabilization or a more exhaustive positioning reset. Risk/reward is currently skewed toward a value trap rather than a clean mean reversion.
• If forcing exposure, structure a bullish call spread in SLM over 3-6 months rather than stock: upside is tied to modest multiple repair, while downside is limited if the policy overhang reasserts itself.
• Pair trade: long a diversified financial compounder or bank ETF against short SLM for 2-4 months. The thesis is that market will continue to reward balance-sheet diversity and funding flexibility over single-name student-lending exposure.
• For event-driven traders, use SLM only around guidance prints: buy on any post-earnings drawdown if management reiterates 2026 guidance and originations remain positive; otherwise fade rallies that are not backed by improving credit or funding metrics.
• Do not short aggressively into weakness unless student-loan policy headlines worsen; the stock has already de-rated meaningfully, so outright downside from here is more likely to come from earnings revisions than multiple compression.